The study’s primary objective was to determine if a brief, 3-month challenge with finasteride would improve selection of patients with elevated PSA for prostate biopsy as well as to examine the impact of finasteride on other prostate cancer biomarkers. The gene discussed is KLK3; the disease is prostate cancer.